AstraZenecaGB0009895292AZNAZN
Financials
Market Cap
$234.53B5Y beta
0.37EPS (TTM)
$4.063Free Float
1.50BP/E ratio (TTM)
37.24Revenue (TTM)
$47.70BEBITDA (TTM)
$13.80BFree Cashflow (TTM)
$1.32BPricing
Analyst Ratings
The price target is $160.17 and the stock is covered by 29 analysts.
Buy
23
Hold
5
Sell
1
Information
AstraZeneca PLC is a science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory and immunology. Its pipeline forms a portfolio of investigational therapies in various stages of clinical development and includes the Alexion Rare Disease portfolio comprising approximately 178 projects. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its BioPharmaceuticals products include Farxiga, Lokelma, Crestor, Breztri and others. It is also focused on discovering, developing, and manufacturing of T-cell receptor therapies. It also offers investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus.